By Sabela Ojea
Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury.
The stock was up 5.3% to 84 cents in Thursday trading. Shares have surged 48% over the past 12 months.
The company said that treatment with nasal anti-CD3 led to marked improvements in motor function among the injured models.
"We are swiftly advancing towards expanding our nasal foralumab technology from successful applications in neurologic diseases like secondary progressive multiple sclerosis to now encompass spinal cord injury," Chief Executive Ivor Elrifi said.
A spinal cord injury involves damage to the spinal cord and can include its nerves.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 23, 2025 15:48 ET (20:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.